MDA5 variants trade antiviral activity for protection from autoimmune

disease

Chris Wallace[1,2,*], Rahul Singh[1,3], Yorgo Modis[1,3,*]

[1]Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge

School of Clinical Medicine, Cambridge CB2 0AW, UK

[2]MRC Biostatistics Unit, University of Cambridge, Cambridge CB2 0SR, UK

[3]Molecular Immunity Unit, Department of Medicine, University of Cambridge, MRC Laboratory of

Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK

*Correspondence: C.W., cew54@cam.ac.uk; Y.M., ymodis@mrc-lmb.cam.ac.uk

Running title: MDA5 variants offer a fitness trade-off

Abstract

Loss-of-function variants in MDA5, a key sensor of double-stranded RNA from viruses and

retroelements, have been associated with protection from type 1 diabetes (T1D) in genome-wide

association studies (GWAS). MDA5 loss-of-function variants have also been reported to increase the risk

of inflammatory bowel disease (IBD). Whether these associations are linked or extend to other diseases

remains unclear. Here, fine-mapping analysis of four large GWAS datasets shows that T1D-protective

loss-of-function MDA5 variants also protect against psoriasis and hypothyroidism, while increasing the

risk of IBD. The degree of autoimmune protection and IBD risk were linearly proportional. The

magnitudes of the odds ratios for autoimmune protection and IBD risk were larger for rare MDA5

variants than for common variants, which were differentially expressed in different geographic

populations. Our analysis suggests MDA5 genetic variants offer a direct fitness trade-off between viral

clearance and autoimmune tissue damage.

Keywords: human genetic variants / genome-wide association studies (GWAS) / autoimmune disease /

inflammatory bowel disease (IBD) / fitness trade-off

Introduction

Innate immune responses must be sensitive enough to detect infection yet specific enough to avoid

activation by cellular components. A key innate immune receptor for cytosolic double-stranded RNA

(dsRNA), a potent signature of viral infection, is MDA5 (Berke & Modis, 2012; Kato *et al*, 2006; Peisley

et al, 2011; Yu *et al*, 2021; Yu *et al*, 2018). Recognition of dsRNA by MDA5 induces a potent IFN-β

response (Berke & Modis, 2012; Peisley *et al*., 2011). The ATPase activity and dsRNA binding

cooperativity of MDA5 confer the necessary sensitivity and specificity of MDA5-dsRNA recognition

(Singh *et al*, 2024b; Yu *et al*., 2021; Yu *et al*., 2018). Mutations in the gene encoding MDA5, *IFIH1*, can

perturb the balance between sensitive and specific dsRNA recognition. *IFIH1* is a hotspot for natural

variants with clinical associations. Approximately 40 gain-of-function missense variants have been

associated with interferonopathies (Rice *et al*, 2020; Rodero & Crow, 2016; Rutsch *et al*, 2015). These

variants promote formation of MDA5 signaling complexes, including on endogenous dsRNAs, by either

increasing the RNA binding affinity of MDA5 or inhibiting its ATP-dependent proofreading activity

(Garau *et al*, 2019; Rice *et al*., 2020; Yu *et al*., 2021). Loss-of-function MDA5 variants cause recurrent

infections (Lamborn *et al*, 2017), and have been reported to contribute to inflammatory bowel disease

(IBD), including ulcerative colitis and Crohn's disease (Adiliaghdam *et al*, 2022; Cananzi *et al*, 2021).

GWAS data have also associated loss-of-function MDA5 variants with reduced risk of developing certain

autoimmune diseases, most notably T1D (Downes *et al*, 2010; Gorman *et al*, 2017; Liu *et al*, 2009;

Nejentsev *et al*, 2009; Smyth *et al*, 2006; Vasseur *et al*, 2011). Specifically, variants E627* (rs35744605),

R843H (rs3747517), I923V (rs35667974), and T946A (rs1990760) have been identified as T1D-

protective (de Azevedo Silva *et al*, 2015; Gorman *et al*., 2017; Jermendy *et al*, 2018; Liu *et al*., 2009;

Nejentsev *et al*., 2009; Smyth *et al*., 2006; Vasseur *et al*., 2011). The E627* and I923V variants are rare,

with allele frequencies of 1-2%, while R843H and T946A are common. These common variants are

differentially expressed in different geographic populations. The T946A variant is present in 70-80% of

Africans and Asians but only 30-50% of Caucasians (de Azevedo Silva *et al*., 2015; Gorman *et al*., 2017;

Liu *et al*., 2009; Nejentsev *et al*., 2009; Vasseur *et al*., 2011). Similarly, the R843H variant is found in

70% of Asians but only 30-40% of Caucasians and Africans (de Azevedo Silva *et al*., 2015; Gorman *et*

al., 2017; Liu *et al*., 2009; Nejentsev *et al*., 2009; Vasseur *et al*., 2011). Most human *IFIH1* reference

sequences contain the alleles that are most common in Asians (Ala946/His843). These coding variants

inhibit the formation of MDA5-dsRNA signaling complexes (Gorman *et al*., 2017; Shigemoto *et al*, 2009)

by reducing the RNA binding affinity of MDA5 or hyperactivating its ATPase activity (Singh *et al*,

2024a). Other loss-of-function variants are splice donor variants that reduce splicing efficiency and hence

mRNA levels (Downes *et al*., 2010).

A robust clinical link has emerged between T1D onset and recent infection with RNA viruses, in

particular coxsackieviruses and other enteroviruses (Yeung *et al*, 2011). T1D patients have more frequent

and persistent enterovirus infections, which precede the appearance of prediabetic markers, including

autoantibodies (Hyoty & Taylor, 2002). MDA5 recognizes RNA from *Picornaviridae*, including

enteroviruses (Kato *et al*., 2006; Wang *et al*, 2010), which have evolved mechanisms to suppress IFN-β

transcription (Hato *et al*, 2007; Visser *et al*, 2019). MDA5-induced inflammation in the pancreas

following rotavirus infection contributes to autoimmune destruction of pancreatic β-cells (Dou *et al*,

2017). Therefore, a plausible hypothesis is that MDA5-dependent inflammation following viral infection

can trigger autoimmune β-cell killing.

Gastrointestinal viral infection has also been linked to IBD onset(Axelrad *et al*, 2019). Intestinal

cells from IBD patients harboring loss-of-function MDA5 variants had elevated viral loads and were

compromised in their ability to maintain epithelial barrier integrity upon further exposure to the enteric

virome (Adiliaghdam *et al*., 2022). Hence, the frequency and clinical phenotypes of MDA5 loss-of-

function variants in IBD patients suggest that MDA5 deficiency contributes to the induction of IBD

(Adiliaghdam *et al*., 2022; Cananzi *et al*., 2021), due in part to increased exposure and susceptibility to

viral infection (Adiliaghdam *et al*., 2022; Lamborn *et al*., 2017).

Results and discussion

Loss-of-function MDA5 variants have been associated with recurrent infection (Lamborn *et al*., 2017),

T1D protection (Downes *et al*., 2010; Gorman *et al*., 2017; Liu *et al*., 2009; Nejentsev *et al*., 2009; Smyth

et al., 2006; Vasseur *et al*., 2011), and IBD risk (Adiliaghdam *et al*., 2022; Cananzi *et al*., 2021).

However, whether these associations are linked, or whether they apply to autoimmune disease more

broadly, has not been explored. We addressed these questions by utilizing larger, more recent GWAS

studies to conduct a broader, more sensitive survey of immune-mediated disease associations involving

MDA5 variants. For our analysis, we selected GWAS datasets to maximize the likelihood of accurate fine

mapping – balancing the need for large sample size, minimizing the use of imputed genotypes, and using

ancestries that best matched the reference panel used to derive linkage disequilibrium (LD) estimates

(Karczewski *et al*, 2024; Liu *et al*, 2015; Robertson *et al*, 2021; Tsoi *et al*, 2017) (see **Materials and**

methods). By reviewing associations with a reported lead T1D-associated variant, I923V (rs35667974)

(Nejentsev *et al*., 2009) we identified psoriasis, hypothyroidism, Crohn's disease, and ulcerative colitis as

additional associated diseases. Fine-mapping analysis using GWAS summary data for these five diseases

identified four variants likely to be causally associated with a subset of the diseases, with considerable

overlap of variants between diseases (**Fig. 1, Table I**). Two of these variants were coding variants, I923V

and T946A, and two were splice donor variants, rs35337543 and rs35732034. All four variants were

previously associated with T1D protection (Downes *et al*., 2010; Gorman *et al*., 2017; Liu *et al*., 2009;

Nejentsev *et al*., 2009; Smyth *et al*., 2006; Vasseur *et al*., 2011).

Given the overlaps between diseases, and the small *P* values observed for fine-mapped variants in

one disease when considering another, we called associated variants by considering marginal association

at any of these variants or other known loss-of-function variants not in LD with any of the index variants

using a stringent Bonferroni correction. This identified associations of a fifth variant, E627*

(rs35744605), with psoriasis, and hypothyroidism (**Fig. 1**). While T946A is common, the other variants

are rare (allele frequency below 3%). Fine-mapping analysis did not find evidence for causality for

variants E627* and R843H (**Table I**). However, for E627* the lack of evidence of causality is likely due

to its low allele frequency (0.7%), which limits power in genetics studies. In contrast, association of

R843H with T1D protection is likely attributable to LD with the co-occurring causal T946A allele (r^2 =

0.60), as previously reported (Gorman *et al*., 2017; Liu *et al*., 2009; Nejentsev *et al*., 2009). Supporting

these conclusions, our accompanying biochemical and structural study of T1D-protective MDA5 variants

shows that the E627* variant lacks signaling activity due to a loss of RNA binding affinity, whereas the

R843H substitution had no effect on the structural, biochemical or signaling activities of MDA5 (Singh *et*

al., 2024a).

Comparing associations across diseases, we found that all five associated variants offered

protection against T1D, psoriasis and hypothyroidism, but increased the risk of ulcerative colitis and

Crohn's disease (**Fig. 2a**). Remarkably, a strict correlation was observed between protection and risk

(**Fig. 2b**). A statistical test of proportionality (see **Materials and methods**) concluded that changes in risk

were linearly proportional across variants (**Fig. 2c**). Additionally, the magnitudes of the odds ratios were

larger for the rare variants than for the common variants. Thus, the rarest variant, I923V, conferred the

greatest degree of T1D protection and the greatest risk of IBD, whereas the most common variant,

T946A, was associated with the least T1D protection and IBD risk (**Fig. 2a-b**). Notably, the T946A

variant, while common in all populations, is the major allele in Asian and African populations but the

minor allele in Caucasians.

Our GWAS meta-analysis uncovers a direct correlation between protection from autoimmune-

related diseases (T1D, psoriasis and hypothyroidism) and increased risk of IBD. The implication is that

calibration of MDA5-dependent antiviral signaling offers a fundamental fitness trade-off. Loss-of-

function MDA5 variants protect from autoimmune tissue damage, including to pancreatic β-cells leading

to T1D, but increase the risk of inflammatory tissue damage from persistent infection, including by

enteric viruses in intestinal epithelia leading to IBD. This model predicts that gain-of-function MDA5

variants protect from chronic inflammation and IBD by ensuring infections are cleared but do so at the

cost of increasing the risk of T1D and other autoimmune diseases.

Materials and methods

GWAS meta-analysis

GWAS summary data for a reported lead T1D-associated variant, I923V (rs35667974) were downloaded

for the following diseases: T1D (16,000 T1D cases, 25,000 controls) (Robertson *et al.*, 2021); IBD (5,956

Crohn's disease cases, 6,968 ulcerative colitis cases, 21,770 controls) (Liu *et al.*, 2015); psoriasis (19,032

cases, 286,769 controls) (Tsoi *et al.*, 2017); and hypothyroidism (20,563 cases, 399,910 controls)

(Karczewski *et al*., 2024). Data were downloaded from the GWAS catalog from the following

repositories: ulcerative colitis, https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003001-

GCST004000/GCST003045/harmonised/26192919-GCST003045-EFO_0000729.h.tsv.gz

(ImmunoChip); Crohn's disease,

https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003001-

GCST004000/GCST003044/harmonised/26192919-GCST003044-EFO_0000384.h.tsv.gz

(ImmunoChip); T1D, https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90013001-

GCST90014000/GCST90013445/GCST90013445_buildGRCh38.tsv (ImmunoChip); Psoriasis:

http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST005001-

GCST006000/GCST005527/harmonised/23143594-GCST005527-EFO_0000676.h.tsv.gz   (Meta

analysis); Hypothyroidism: https://pan-ukb-us-east-1.s3.amazonaws.com/sumstats_flat_files/categorical-

20002-both_sexes-1453.tsv.bgz (genome wide SNP chip). These studies were selected to balance the

need for large studies and those most likely to give accurate results in fine mapping – i.e. those which

minimized imputation and most closely matched the ancestry of our reference LD panel.

Alleles were aligned to the UK Biobank as a common reference. Reference LD matrices were

estimated from 40,000 European subjects from UK Biobank. Fine mapping was performed with a variant

of the Sum of Single Effects (SuSiE) (Wang *et al*, 2020) model, as implemented in susieR (Zou *et al*,

2022).

rs72871627 was selected as a tag ($r^2 = 0.99$) of the splice donor variant rs35337543 because

rs72871627 was available in all GWAS datasets whereas rs35337543 was only available in the T1D

GWAS dataset.

Tests of proportional effects between pairs of diseases were performed across all variants in Table I

using colocPropTest [https://cran.r-project.org/package=colocPropTest] which implements the test of

proportionality as previously described (Wallace, 2013).

Data Availability

This study is a meta-analysis of previously published data. All code to reproduce this analysis is available

at Zenodo.org [https://doi.org/10.5281/zenodo.12771481].

Competing Interests

Y.M. is a consultant for Related Sciences LLC. C.E.W. is a part time employee at GSK. GSK was not

involved in this study. R.S. has no competing interests or conflicts to declare.

Author Contributions

Conceptualization, C.E.W., R.S. and Y.M.; Methodology, C.E.W.; Formal Analysis, C.E.W. and Y.M.;

Funding Acquisition, Y.M.; Project Administration, Y.M.; Software, C.E.W.; Supervision, Y.M.; Writing

– Original Draft, Y.M.; Writing – Review & Editing, C.E.W., R.S. and Y.M.

Acknowledgements

We thank Louise Modis, Tetsuo Hasegawa, and the Modis group for useful discussions. This work was

supported by the Wellcome Trust [217191/Z/19/Z to Y.M.] and [WT220788 to C.E.W], and the Medical

Research Council [MC_UU_00040/01 to C.E.W.].

References

Adiliaghdam F, Amatullah H, Digumarthi S, Saunders TL, Rahman RU, Wong LP, Sadreyev R, Droit L,

Paquette J, Goyette P *et al* (2022) Human enteric viruses autonomously shape inflammatory bowel

disease phenotype through divergent innate immunomodulation. *Sci Immunol* 7: eabn6660

Axelrad JE, Olen O, Askling J, Lebwohl B, Khalili H, Sachs MC, Ludvigsson JF (2019) Gastrointestinal

Infection Increases Odds of Inflammatory Bowel Disease in a Nationwide Case-Control Study. *Clin*

Gastroenterol Hepatol 17: 1311-1322 e1317

Berke IC, Modis Y (2012) MDA5 cooperatively forms dimers and ATP-sensitive filaments upon binding

double-stranded RNA. *EMBO J* 31: 1714-1726

Cananzi M, Wohler E, Marzollo A, Colavito D, You J, Jing H, Bresolin S, Gaio P, Martin R, Mescoli C *et*

al (2021) IFIH1 loss-of-function variants contribute to very early-onset inflammatory bowel disease.

Hum Genet 140: 1299-1312

de Azevedo Silva J, Tavares NA, Santos MM, Moura R, Guimaraes RL, Araujo J, Crovella S, Brandao

LA (2015) Meta-analysis of STAT4 and IFIH1 polymorphisms in type 1 diabetes mellitus patients

with autoimmune polyglandular syndrome type III. *Genet Mol Res* 14: 17730-17738

Dou Y, Yim HC, Kirkwood CD, Williams BR, Sadler AJ (2017) The innate immune receptor MDA5

limits rotavirus infection but promotes cell death and pancreatic inflammation. *EMBO J* 36: 2742-

2757

Downes K, Pekalski M, Angus KL, Hardy M, Nutland S, Smyth DJ, Walker NM, Wallace C, Todd JA

(2010) Reduced expression of IFIH1 is protective for type 1 diabetes. *PLoS One* 5

Garau J, Cavallera V, Valente M, Tonduti D, Sproviero D, Zucca S, Battaglia D, Battini R, Bertini E,

Cappanera S *et al* (2019) Molecular Genetics and Interferon Signature in the Italian Aicardi Goutieres

Syndrome Cohort: Report of 12 New Cases and Literature Review. *J Clin Med* 8: 750

Gorman JA, Hundhausen C, Errett JS, Stone AE, Allenspach EJ, Ge Y, Arkatkar T, Clough C, Dai X,

Khim S *et al* (2017) The A946T variant of the RNA sensor IFIH1 mediates an interferon program that

limits viral infection but increases the risk for autoimmunity. *Nat Immunol* 18: 744-752

Hato SV, Ricour C, Schulte BM, Lanke KH, de Bruijni M, Zoll J, Melchers WJ, Michiels T, van

Kuppeveld FJ (2007) The mengovirus leader protein blocks interferon-alpha/beta gene transcription

and inhibits activation of interferon regulatory factor 3. *Cell Microbiol* 9: 2921-2930

Hyoty H, Taylor KW (2002) The role of viruses in human diabetes. *Diabetologia* 45: 1353-1361

Jermendy A, Szatmari I, Korner A, Szabo AJ, Toth-Heyn P, Hermann R (2018) Association between

interferon-induced helicase (IFIH1) rs1990760 polymorphism and seasonal variation in the onset of

type 1 diabetes mellitus. *Pediatr Diabetes* 19: 300-304

Karczewski KJ, Gupta R, Kanai M, Lu W, Tsuo K, Wang Y, Walters RK, Turley P, Callier S, Baya N *et*

al (2024) Pan-UK Biobank GWAS improves discovery, analysis of genetic architecture, and

resolution into ancestry-enriched effects. *bioRxiv*: 2024.2003.2013.24303864

Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii

KJ *et al* (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.

Nature 441: 101-105

Lamborn IT, Jing H, Zhang Y, Drutman SB, Abbott JK, Munir S, Bade S, Murdock HM, Santos CP,

Brock LG *et al* (2017) Recurrent rhinovirus infections in a child with inherited MDA5 deficiency. *J*

Exp Med 214: 1949-1972

Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T

et al (2015) Association analyses identify 38 susceptibility loci for inflammatory bowel disease and

highlight shared genetic risk across populations. *Nat Genet* 47: 979-986

Liu S, Wang H, Jin Y, Podolsky R, Reddy MV, Pedersen J, Bode B, Reed J, Steed D, Anderson S *et al*

(2009) IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene

expression in peripheral blood mononuclear cells. *Hum Mol Genet* 18: 358-365

Nejentsev S, Walker N, Riches D, Egholm M, Todd JA (2009) Rare variants of IFIH1, a gene implicated

in antiviral responses, protect against type 1 diabetes. *Science* 324: 387-389

Peisley A, Lin C, Wu B, Orme-Johnson M, Liu M, Walz T, Hur S (2011) Cooperative assembly and

dynamic disassembly of MDA5 filaments for viral dsRNA recognition. *Proc Natl Acad Sci U S A* 108:

21010-21015

Rice GI, Park S, Gavazzi F, Adang LA, Ayuk LA, Van Eyck L, Seabra L, Barrea C, Battini R, Belot A *et*

al (2020) Genetic and phenotypic spectrum associated with IFIH1 gain-of-function. *Hum Mutat* 41:

837-849

Robertson CC, Inshaw JRJ, Onengut-Gumuscu S, Chen WM, Santa Cruz DF, Yang H, Cutler AJ, Crouch

DJM, Farber E, Bridges SL, Jr. *et al* (2021) Fine-mapping, trans-ancestral and genomic analyses

identify causal variants, cells, genes and drug targets for type 1 diabetes. *Nat Genet* 53: 962-971

Rodero MP, Crow YJ (2016) Type I interferon-mediated monogenic autoinflammation: The type I

interferonopathies, a conceptual overview. *J Exp Med* 213: 2527-2538

Rutsch F, MacDougall M, Lu C, Buers I, Mamaeva O, Nitschke Y, Rice GI, Erlandsen H, Kehl HG,

Thiele H *et al* (2015) A specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome.

Am J Hum Genet 96: 275-282

Shigemoto T, Kageyama M, Hirai R, Zheng J, Yoneyama M, Fujita T (2009) Identification of loss of

function mutations in human genes encoding RIG-I and MDA5: implications for resistance to type I

diabetes. *J Biol Chem* 284: 13348-13354

Singh R, Herrero Del Valle A, Joiner J, Zwaagstra M, Ferguson BJ, Kuppeveld FJM, Modis Y (2024a)

Molecular basis of pathogenesis and protection from type 1 diabetes by loss of function MDA5

variants. bioR*xiv*: *2024.10.03.616466*

Singh R, Wu Y, Herrero Del Valle A, Leigh KE, Mong S, Cheng MTK, Ferguson BJ, Modis Y (2024b)

Contrasting functions of ATP hydrolysis by MDA5 and LGP2 in viral RNA sensing. *J Biol Chem* 300:

105711

Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, Guja C, Ionescu-Tirgoviste C, Widmer B,

Dunger DB *et al* (2006) A genome-wide association study of nonsynonymous SNPs identifies a type 1

diabetes locus in the interferon-induced helicase (IFIH1) region. *Nat Genet* 38: 617-619

Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, Ellinghaus E, Barker JN, Chandran

V, Dand N *et al* (2017) Large scale meta-analysis characterizes genetic architecture for common

psoriasis associated variants. *Nat Commun* 8: 15382

Vasseur E, Patin E, Laval G, Pajon S, Fornarino S, Crouau-Roy B, Quintana-Murci L (2011) The

selective footprints of viral pressures at the human RIG-I-like receptor family. *Hum Mol Genet* 20:

4462-4474

Visser LJ, Langereis MA, Rabouw HH, Wahedi M, Muntjewerff EM, de Groot RJ, van Kuppeveld FJM

(2019) Essential Role of Enterovirus 2A Protease in Counteracting Stress Granule Formation and the

Induction of Type I Interferon. *J Virol* 93

Wallace C (2013) Statistical testing of shared genetic control for potentially related traits. *Genet*

Epidemiol 37: 802-813

Wang G, Sarkar A, Carbonetto P, Stephens M (2020) A simple new approach to variable selection in

regression, with application to genetic fine mapping. *J R Stat Soc Series B Stat Methodol* 82: 1273-

1300

Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW (2010) MDA5 and MAVS

mediate type I interferon responses to coxsackie B virus. *J Virol* 84: 254-260

Yeung WC, Rawlinson WD, Craig ME (2011) Enterovirus infection and type 1 diabetes mellitus:

systematic review and meta-analysis of observational molecular studies. *BMJ* 342: d35

Yu Q, Herrero Del Valle A, Singh R, Modis Y (2021) MDA5 disease variant M854K prevents ATP-

dependent structural discrimination of viral and cellular RNA. *Nat Commun* 12: 6668

Yu Q, Qu K, Modis Y (2018) Cryo-EM Structures of MDA5-dsRNA Filaments at Different Stages of

ATP Hydrolysis. *Mol Cell* 72: 999-1012 e1016

Zou Y, Carbonetto P, Wang G, Stephens M (2022) Fine-mapping from summary data with the "Sum of

Single Effects" model. *PLoS genetics* 18: e1010299

Fig. 1. Manhattan plots of fine-mapped variants for five diseases. Colored circles indicate the fine

mapping sets identified, and colored text labels the most likely causal SNP in each set, selected due its

known function on MDA5. Known loss-of-function SNPs that were not in any fine mapping set are

marked with "x" and a black label. Lower right, minor allele frequency (MAF) and function of fine-

mapped SNPs.

Figure 2. GWAS meta-analysis of loss-of-function MDA5 variants. (a) Effect sizes expressed in terms of the odd ratio for selected MDA5 loss-of-function variants. ‡Because rs35337543 was only available in two GWAS datasets, rs72871627 (r^2 = 0.973) was used as a tag for rs35337543. EAF, effect allele frequency. Error bars, SEM. ns, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 5×10⁻⁸ (genome-wide significance), where P is the Bonferroni-adjusted P value from marginal association analysis. CV, likely causal variant present in a credible set in fine-mapping analysis. R843H was included in fine-mapping analysis but excluded from marginal association analysis. See **Table I**. **(b)** Odds ratio plot for variants and diseases in *(a)*. **(c)** Estimated effect sizes in hypothyroidism compared to the other diseases. Hypothyroidism was selected because it was the largest dataset for which all SNPs were available. Dashed lines, identity and negative identity lines.

292 **Table I. Marginal association and fine-mapping analysis results.**

Variant	SNP	Location	Allele	EAF	Disease	lnOR ± std. err.	OR	P	$P_{Bonferroni}$	Causal[‡]
I923V	rs35667974	2:162268127	T>C	0.022	T1D	-0.493 ± 0.062	0.611	1.21×10^{-15}	2.91×10^{-14}	T
					Psoriasis	-0.440 ± 0.129	0.644	6.68×10^{-4}	0.0160	F
					Hypothyr.	-0.254 ± 0.038	0.776	2.98×10^{-11}	7.16×10^{-10}	T
					Crohn's	0.121 ± 0.046	1.129	8.08×10^{-3}	0.1938	F
					UC	0.276 ± 0.046	1.318	1.94×10^{-9}	4.64×10^{-8}	T
Splice1	rs35732034	2:162268086	C>T	0.010	Psoriasis	-0.693 ± 0.253	0.500	6.25×10^{-3}	0.1500	F
					T1D	-0.464 ± 0.083	0.629	2.29×10^{-8}	5.50×10^{-7}	T
					Hypothyr.	-0.230 ± 0.056	0.794	4.47×10^{-5}	1.07×10^{-3}	F
					UC	0.180 ± 0.067	1.197	7.70×10^{-3}	0.1848	F
					Crohn's	0.226 ± 0.064	1.253	4.15×10^{-4}	9.96×10^{-3}	F
Splice2*	rs72871627	2:162280432	A>G	0.015	Psoriasis	-0.541 ± 0.200	0.582	6.81×10^{-3}	0.1634	F
					T1D	-0.458 ± 0.073	0.633	4.19×10^{-10}	1.00×10^{-8}	T
					Hypothyr.	-0.253 ± 0.046	0.777	2.94×10^{-8}	7.05×10^{-7}	T
					Crohn's	0.072 ± 0.056	1.074	0.1990	1	F
					UC	0.308 ± 0.054	1.360	1.19×10^{-8}	2.85×10^{-7}	T
Splice2	rs35337543	2:162279995	C>G	0.015	T1D	-0.458 ± 0.073	0.633	4.19×10^{-10}	ND	T
					Hypothyr.	-0.236 ± 0.045	0.790	1.51×10^{-7}	ND	T
E627*	rs35744605	2:162277580	C>A	0.007	Hypothyr.	-0.273 ± 0.068	0.761	5.63×10^{-5}	1.35×10^{-3}	F
					Psoriasis	-0.210 ± 0.372	0.810	0.5717	1	F
T946A	rs1990760	2:162267541	T>C	0.389	Psoriasis	-0.192 ± 0.034	0.825	1.95×10^{-8}	4.68×10^{-7}	T
					T1D	-0.132 ± 0.013	0.876	5.57×10^{-24}	1.34×10^{-22}	T
					Hypothyr.	-0.080 ± 0.011	0.923	5.61×10^{-13}	1.35×10^{-11}	T
					Crohn's	0.053 ± 0.013	1.055	3.36×10^{-5}	8.07×10^{-4}	F
					UC	0.086 ± 0.013	1.089	1.78×10^{-10}	4.27×10^{-9}	T
R843H	rs3747517	2:162272314	C>T	0.276	T1D	-0.111 ± 0.014	0.895	2.94×10^{-15}	ND	F
					Psoriasis	-0.103 ± 0.035	0.903	3.72×10^{-3}	ND	F
					Hypothyr.	-0.068 ± 0.012	0.934	1.85×10^{-8}	ND	F
					Crohn's	0.030 ± 0.014	1.031	0.0301	ND	F
					UC	0.051 ± 0.014	1.053	3.85×10^{-4}	ND	F
N160D	rs74162075	2-162310909	T>C	0.001	Psoriasis	-2.057 ± 0.811	0.128	0.0111	0.2674	F
					Hypothyr.	-0.270 ± 0.133	0.763	0.0427	1	F

293 EAF, effect allele frequency; OR, odds ratio.
294 *rs72871627 was used as a tag of rs35337543 because the latter was not available in all GWAS datasets.
295 ‡Causality was inferred from presence of the SNP in a credible set in fine mapping analysis.
296 Dashed lines indicate that the SNPs above and below the line are in LD with each other.